Robert Sutherland Smith is again proving that he is still alive with another guest post. Robert started his City career the year before I was born and is, I think, 157 years old. Fear not. He is very much alive and kicking. He and I have worked together for almost eight years at t1ps.com . He is my friend and he is a very funny and intelligent chap. He is now branching out to celebrate his 158th by doing some freelance writing over at various places ( including Shareprophets.com naturally) on FTSE 350 Income stocks. Robert is a speaker at the UKInvestor Show on April 5th 2014. He is a great one for focussing on yield. RSS today looks at AstraZeneca. RSS writes:
With the first quarter’s results from Astra Zeneca (AZN) the curtain has gone up for the first act of what we all know will be a tough and difficult year; a stock market version of Gounod’s Faust but with a happier ending we trust. At least that is what the market expects to judge from the fact that the share price has risen some ten per cent from since the introduction and appointment of the new Chief Executive (whose name almost rhymes with Poirot) and his plan plus the fact the share price did not fall significantly on their publication - ending down 4.5p on the day to 3321p a share. His plan is to transform the company from its co-operative, external economy dividend favouring model, back to the drug discovery orthodoxy of more internally funded research and development; leaving the question hanging in the air about whether the company can increase internal R&D spending while at the same time maintain and increase dividends?